Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy

PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with poor prognosis. This study compared patient characteristics, comorbidities, adverse events (AEs), treatment persistence, healthcare resource utilization (HRU) and costs in patients with metastatic MCC (mMCC) treated with imm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clinicoecon Outcomes Res
Autori principali: Zheng, Ying, Yu, Ting, Mackey, Rachel H, Gayle, Julie A, Wassel, Christina L, Phatak, Hemant, Kim, Ruth
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove 2021
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8001053/
https://ncbi.nlm.nih.gov/pubmed/33790597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S290768
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi